TICKERNERD
Menu
SMMTSMMTHealthcare · Biotechnology

SMMT Stock Forecast: Summit Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$18
+3.24% on the day

The 17 Wall Street analysts covering Summit Therapeutics, Inc. hold a median 12-month price target of $33 — +90.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$14.0B
Ticker Nerd rank
21 / 100
Median analyst target
$33
Analysts covering
17
Revenue$0.0
Operating income−$220.5M
Net income−$215.7M
Free cash flow−$142.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.5%
1M
+16.1%
YTD
+0.3%
1Y
−5.6%
From 52W high
−33.5%
From 52W low
+41.2%
$12
$26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SMMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Summit Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
86
Accruals
52
Growth
48
Volatility
39
Revisions
39
Quality
27
Issuance
26
Momentum
17
Size
12

Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (17): The shares have been drifting down relative to others.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SMMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SMMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40Oct 25Jan 26Apr 26Jul 26SMMTHigh $42Median $33Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
11 Buy6 Hold0 Sell
Low $11Median $33High $42

The green dot is the last close — the median target sits +90.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
9 Sept 2026JefferiesUpgradeBuy$15 → $25
26 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
25 Aug 2026BernsteinUpgradeMarket Perform$9.80 → $12
18 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
18 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
12 Aug 2026Leerink PartnersUpgradeMarket Perform$12 → $13
12 Aug 2026Leerink PartnersUpgradeMarket Perform—
24 July 2026GuggenheimMaintainsBuy—
24 July 2026GuggenheimMaintainsBuy$40 → $38
24 July 2026StifelMaintainsBuy$45 → $38
24 July 2026StifelMaintainsBuy—
23 July 2026HC Wainwright & Co.ReiteratesNeutral—
23 July 2026HC Wainwright & Co.ReiteratesNeutral—
22 May 2026BernsteinInitiatesUnderperform$7.70
22 May 2026BernsteinInitiatesUnderperform—
22 May 2026HC Wainwright & Co.DowngradeNeutral—
22 May 2026HC Wainwright & Co.DowngradeNeutral—
4 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026Piper SandlerMaintainsNeutral—
8 Apr 2026StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SMMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SMMT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Summit Therapeutics, Inc. returned −5.6% against +17.5% for the S&P 500, dividends included.

SMMT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26SMMTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SMMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Summit Therapeutics, Inc. (SMMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.0×

Cheaper than 30% of US stocks

Price / sales
—
Price / book
22.1×

Cheaper than 4% of US stocks

EV / EBITDA
−15.2×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−192.5%

Higher than 8% of US stocks

Return on assets
−101.6%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Summit Therapeutics, Inc. (SMMT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Summit Therapeutics, Inc. has a market value of $14.0B and an enterprise value of $13.3B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$856.0M.

  • Diluted earnings per share, trailing twelve months: $−1.12.

  • Free cash flow in the twelve months to 30 June 2026: −$459.8M, after $1.4M of capital spending.

  • Shares outstanding: 793.1M.

  • Trailing P/E: 25.0×; forward P/E: −14.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Summit Therapeutics, Inc. employs 265 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SMMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SMMTSummit Therapeutics, Inc.$14.0B
21
BBIOBridgeBio Pharma, Inc.$14.0B
68
EXELExelixis, Inc.$14.6B
98
BMRNBioMarin Pharmaceutical, Inc.$12.7B
64
JAZZJazz Pharmaceuticals Plc$15.4B
99
MDGLMadrigal Pharmaceuticals, Inc.$12.3B
69
HALOHalozyme Therapeutics, Inc.$12.2B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Summit Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SMMT news & analysis

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China

Business Wire · 13 Sept 2026positive

Summit Therapeutics noted that its partner Akeso will present updated data, including overall survival, from the randomized Phase III HARMONi-2 trial of ivonescimab at the WCLC 2026 conference in Seoul, South Korea. The trial demonstrated a statistically significant and clinically meaningful benefit for ivonescimab monotherapy compared with pembrolizumab monotherapy in PD-L1-positive advanced non-small cell lung cancer patients in China.

Why it matters — SMMT watchers would care because the presentation of positive Phase III data on its partner's investigational bispecific antibody ivonescimab highlights progress for a key asset in the company's pipeline.

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

Zacks Investment Research · 4 Sept 2026positive

Summit Therapeutics' stock rose 17% after its drug ivonescimab demonstrated a significant overall survival benefit over Keytruda in a China phase III study for non-small cell lung cancer (NSCLC).

Why it matters — Positive survival data for ivonescimab against a leading competitor could signal a meaningful advance for Summit's NSCLC pipeline.

Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study

Benzinga · 3 Sept 2026positive

Summit Therapeutics' stock traded higher after its development partner, Akeso Inc., reported highly favorable overall survival data from a late-stage clinical trial for its cancer therapy ivonescimab in lung cancer. The headline describes the drug as outperforming Keytruda in the study.

Why it matters — Akeso's favorable late-stage survival data for ivonescimab is directly relevant to Summit, as the company is developing the therapy in partnership.

November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet

Seeking Alpha · 3 Sept 2026positive

Summit Therapeutics is positioned as a high-conviction buy ahead of the November 2026 FDA PDUFA decision for ivonescimab in NSCLC, citing robust progression-free survival and statistically significant overall survival benefits in multiple Phase III trials versus PD-1 monotherapy. The company holds over $690 million in cash, providing four to five quarters of runway to fund late-stage clinical catalysts and regulatory milestones.

Why it matters — SMMT watchers would care because the upcoming FDA decision on ivonescimab represents a pivotal regulatory milestone for Summit's lead cancer candidate, with the company's cash position supporting its path to that catalyst.

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Business Wire · 2 Sept 2026positive

Summit Therapeutics noted that its partner Akeso announced positive overall survival results from the randomized, double-blind Phase III HARMONi-2 study, comparing ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic PD-L1-positive non-small cell lung cancer. The study was conducted as a single-region, multi-center trial in China.

Why it matters — As Summit's partnered asset is the subject of this positive overall survival data in a key Phase III indication, a SMMT watcher would care because these results could be relevant to the drug's clinical value and development outlook.

FAQ

Frequently asked questions about SMMT stock

What is the SMMT stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Summit Therapeutics, Inc. have a median 12-month price target of $33, with estimates ranging from $11 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SMMT stock a buy right now?

Of the 17 analysts covering Summit Therapeutics, Inc., 11 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Summit Therapeutics, Inc. 21 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SMMT?

As at 12 Sept 2026, Summit Therapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).

Will SMMT stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +90.7% from the last close, and Ticker Nerd's factor model ranks Summit Therapeutics, Inc. 21 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SMMT stock forecast for 2030?

No analyst covering Summit Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SMMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $42 over the next 12 months.

How has SMMT stock performed over the past year?

Summit Therapeutics, Inc. returned -5.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Summit Therapeutics, Inc. do?

Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs.

What is the latest news on SMMT?

The most recent item we track (Business Wire, 13 Sept 2026): "Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China". Summit Therapeutics noted that its partner Akeso will present updated data, including overall survival, from the randomized Phase III HARMONi-2 trial of ivonescimab at the WCLC 2026 conference in Seoul, South Korea. The trial demonstrated a statistically significant and clinically meaningful benefit for ivonescimab monotherapy compared with pembrolizumab monotherapy in PD-L1-positive advanced non-small cell lung cancer patients in China.

Company

About Summit Therapeutics, Inc.

Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.

CEO Mr. Robert W. Duggan · 265 employees · United States · https://www.smmttx.com